Juniper Biologics Clinches Prestigious Molecular Science & Technology Acquisition of the Year Award at the Acquisition International M&A Awards 2023
SINGAPORE, Jan. 7, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International's M&A Awards 2023.
- SINGAPORE, Jan. 7, 2024 /PRNewswire/ -- Juniper Biologics ("Juniper"), a global science-led pharmaceutical company headquartered in Singapore, proudly announces its latest achievement, winning the award for Molecular Science & Technology Acquisition of the Year at Acquisition International's M&A Awards 2023.
- Now in its seventh year, Acquisition International's M&A Awards recognizes the excellence of top executives, analysts, investors, and professionals in the M&A sector across diverse industries.
- In the healthcare domain, Juniper Biologics stands out for the second consecutive year, this time for its acquisition of Caris Molecular Intelligence®, a tumour profiling service for Asia.
- On being awarded the M&A Awards for the Molecular Science & Technology Acquisition of the Year, Raman Singh, CEO of Juniper Biologics expressed: "We're deeply honored to receive recognition once again, this time for the acquisition of Caris Molecular Intelligence®.